b56-prostate-cancer-programme
Polish NFZ drug programme B.56 for prostate cancer (ICD-10 C61). Use when helping clinicians with patient qualification, drug selection, dosing, monitoring, or follow-up for mHSPC, nmCRPC, or mCRPC treatment with apalutamide, darolutamide, enzalutamide, olaparib, niraparib+abiraterone, or talazoparib. Covers eligibility criteria, required diagnostics, treatment duration, and exclusion criteria.
Installation and usage
Polish NFZ drug programme B.56 for prostate cancer (ICD-10 C61). Use when helping clinicians with patient qualification, drug selection, dosing, monitoring, or follow-up for mHSPC, nmCRPC, or mCRPC treatment with apalutamide, darolutamide, enzalutamide, olaparib, niraparib+abiraterone, or talazoparib. Covers eligibility criteria, required diagnostics, treatment duration, and exclusion criteria.
انسٹال کرنے کے بعد، آپ یہ اسکل ٹرمینل میں درج ذیل کمانڈ چلا کر استعمال کر سکتے ہیں:
skills use b56-prostate-cancer-programme